ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE‐155 STUDY. (12th June 2019) - Gregory, G.; Walker, P.; Mahadevan, D.; Wang, D.; Chang, J.; Hernandez‐Ilizaliturri, F.; Klein, A.; Rybka, W.; Wagner‐Johnston, N.; Escobar, C.; Pagel, J.M.; Mohrbacher, A.; et al.